Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
PLoS One ; 4(1): e4130, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19125189

RESUMEN

BACKGROUND: Development of T-cells based-Interferon gamma (IFNgamma) assays has offered new possibilities for the diagnosis of latent tuberculosis infection (LTBI) and active disease in adults. Few studies have been performed in children, none in France. With reference to the published data on childhood TB epidemiology in the Paris and Ile de France Region, we considered it important to evaluate the performance of IGRA (QuantiFERON TB Gold In Tube(R), QF-TB-IT) in the diagnosis and the follow-up through treatment of LTBI and active TB in a cohort of French children. METHODOLOGY/PRINCIPAL FINDINGS: 131 children were recruited during a prospective and multicentre study (October 2005 and May 2007; Ethical Committee St Louis Hospital, Paris, study number 2005/32). Children were sampled at day 0, 10, 30, 60 (except Healthy Contacts, HC) and 90 for LTBI and HC, and a further day 120, and day 180 for active TB children. Median age was 7.4 years, with 91% of the children BCG vaccinated. LTBI and active TB children undergoing therapy produced significant higher IFNgamma values after 10 days of treatment (p = 0.035). In addition, IFNgamma values were significantly lower at the end of treatment compared to IFNgamma values at day 0, although the number of positive patients was not significantly different between day 0 and end of treatment. CONCLUSIONS/ SIGNIFICANCE: By following quantitative IFNgamma values in each enrolled child with LTBI or active TB and receiving treatment, we were able to detect an increase in the IFNgamma response at day 10 of treatment which might allow the confirmation of a diagnosis. In addition, a decline in IFNgamma values during treatment makes it possible for clinicians to monitor the effect of preventive or curative therapy.


Asunto(s)
Interferón gamma , Tuberculosis/diagnóstico , Tuberculosis/inmunología , Adolescente , Adulto , Vacuna BCG/inmunología , Niño , Preescolar , Femenino , Francia/epidemiología , Humanos , Lactante , Recién Nacido , Interferón gamma/inmunología , Masculino , Estudios Prospectivos , Curva ROC , Juego de Reactivos para Diagnóstico , Factores de Tiempo , Tuberculosis/epidemiología , Tuberculosis/prevención & control
2.
J Antimicrob Chemother ; 58(4): 748-51, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16905527

RESUMEN

We studied 100 well-characterized E. coli blood isolates from patients with urosepsis for their susceptibility to nalidixic acid, ampicillin and trimethoprim-sulfamethoxazole, according to prevalence of virulence factors, phylogenetic groups and subgroups, PAI II(J96)-like domains (determined by physical linkage of cnf1, hly and hra) and PAI I(CFT073)-like domains (determined by physical linkage of papGII to the hly locus). Nalidixic acid resistance was associated with a lower prevalence of sfa/foc, K1 antigen, pathogenicity island II(J96)-like domains, subgroup B2/I and a shift towards group A.


Asunto(s)
Farmacorresistencia Bacteriana/genética , Escherichia coli/efectos de los fármacos , Islas Genómicas/genética , Filogenia , Sepsis/microbiología , Infecciones Urinarias/microbiología , Factores de Virulencia/genética , Ampicilina/farmacología , Antiinfecciosos/farmacología , Escherichia coli/genética , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Ácido Nalidíxico/farmacología , Reacción en Cadena de la Polimerasa , Combinación Trimetoprim y Sulfametoxazol/farmacología
3.
Infect Immun ; 70(6): 3216-26, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12011017

RESUMEN

We characterized 100 Escherichia coli urosepsis isolates from adult patients according to host compromise status by means of ribotyping, PCR phylogenetic grouping, and PCR detection of papG alleles and the virulence-related genes sfa/foc, fyuA, irp-2, aer, hly, cnf-1 and hra. We also tested these strains for copies of pap and hly and their direct physical linkage with other virulence genes in an attempt to look for pathogenicity islands (PAIs) described for the archetypal uropathogenic strains J96, CFT073, and 536. Most of the isolates belonged to E. coli phylogenetic groups B2 and D and bore papG allele II, aer, and fyuA/irp-2. papG allele II-bearing strains were more common in noncompromised patients, while papG allele-negative strains were significantly more frequent in compromised patients. Fifteen ribotypes were identified. The three archetypal strains harbored different ribotypes, and only one-third of our urosepsis strains were genetically related to one of the archetypal strains. Three and 18 strains harbored three and two copies of pap, respectively, and 5 strains harbored two copies of hly. papGIII was physically linked to hly, cnf-1, and hra (reported to be PAI II(J96)-like genetic elements) in 14% of the strains. The PAI II(J96)-like domain was inserted within pheR tRNA in 11 strains and near leuX tRNA in 3 strains. Moreover, the colocalized genes cnf-1, hra, and hly were physically linked to papGII in four strains and to no pap gene in three strains. papGII and hly (reported to be PAI I(CFT073)-like genetic elements) were physically linked in 16 strains, pointing to a PAI I(CFT073)-like domain. Three strains contained both a PAI II(J96)-like domain and a PAI I(CFTO73)-like domain. Forty-two strains harbored papGII but not hly, in keeping with the presence of a PAI II(CFT073)-like domain. Only one strain harbored a PAI I(536)-like domain (hly only), and none harbored a PAI I(J96)-like domain (papGI plus hly) or a PAI II(536)-like domain (papGIII plus hly). This study provides new data on the prevalence and variability of physical genetic linkage between pap and certain virulence-associated genes that are consistent with their colocalization on archetypal PAIs.


Asunto(s)
Bacteriemia/microbiología , Proteínas Bacterianas , Infecciones por Escherichia coli/microbiología , Escherichia coli/genética , Proteínas Fimbrias , Pielonefritis/microbiología , Adhesinas de Escherichia coli/genética , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Bacteriemia/epidemiología , Proteínas de la Membrana Bacteriana Externa/genética , Toxinas Bacterianas/genética , Proteínas Portadoras/genética , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , Citotoxinas/genética , Escherichia coli/clasificación , Infecciones por Escherichia coli/epidemiología , Proteínas de Escherichia coli/genética , Femenino , Francia/epidemiología , Genes Bacterianos , Humanos , Péptidos y Proteínas de Señalización Intercelular , Masculino , Persona de Mediana Edad , Filogenia , Prevalencia , Pielonefritis/epidemiología , Receptores de Superficie Celular/genética , Recombinación Genética , Ribotipificación , Sepsis/microbiología , Virulencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA